{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:31:27Z","timestamp":1783456287916,"version":"3.55.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40265-019-01105-0","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T12:18:10Z","timestamp":1554121090000},"page":"675-679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Relugolix: First Global Approval"],"prefix":"10.1007","volume":"79","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"key":"1105_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/AOG.0000000000003141","volume":"133","author":"Y Osuga","year":"2019","unstructured":"Osuga Y, Enya K, Kudou K, et al. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2019;133:423\u201333.","journal-title":"Obstet Gynecol"},{"key":"1105_CR2","unstructured":"Takeda. Uterine fibroids treatment agent (GnRH antagonists) \u201cRerumina for manufacturing and marketing approval in Japan of Tablets 40\u00a0mg\u201d [media release]. 8 Jan 2019. \n                    https:\/\/www.takeda.com\/jp\/newsroom\/newsreleases\/2019\/20190108-8038\/\n                    \n                  ."},{"key":"1105_CR3","unstructured":"Myovant Sciences. Relugolix Japanese prescribing information; 2019. \n                    http:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/400256_2499013F1027_1_02\n                    \n                   Accessed 7 March 2019."},{"key":"1105_CR4","unstructured":"Takeda, Roivant Sciences. Roivant Sciences and Takeda launch Myovant Sciences to develop innovative therapeutics for women\u2019s health and prostate cancer [media release]. 6 June 2016. \n                    http:\/\/www.takeda.com\n                    \n                  ."},{"key":"1105_CR5","unstructured":"Takeda, Aska Pharmaceutical. ASKA and Takeda enter into licensing agreement for Relugolix in women\u2019s health indications [media release]. 31 May 2018. \n                    http:\/\/www.takeda.com\n                    \n                  ."},{"key":"1105_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejphar.2013.12.001","volume":"723","author":"D Nakata","year":"2014","unstructured":"Nakata D, Masaki T, Tanaka A, et al. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. Eur J Pharmacol. 2014;723:167\u201374.","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 1","key":"1105_CR7","first-page":"i267","volume":"32","author":"A Lukes","year":"2017","unstructured":"Lukes A, Johnson B, Jones L, et al. Pharmacokinetics, pharmacodynamics, and safety of relugolix, a potent oral once-daily gonadotropin-releasing hormone (GnRH) receptor antagonist, as monotherapy and in combination with estradiol\/norethindrone acetate add-back therapy [abstract no. P-287]. Hum Reprod. 2017;32(Suppl 1):i267\u20138.","journal-title":"Hum Reprod"},{"issue":"12","key":"1105_CR8","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1210\/jc.2015-2770","volume":"100","author":"DB MacLean","year":"2015","unstructured":"MacLean DB, Shi H, Faessel HM, et al. Medical castration using the investigational oral GnRH antagonist TAK-385 (relugolix): phase 1 study in healthy males. J Clin Endocrinol Metab. 2015;100(12):4579\u201387.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Supp 1","key":"1105_CR9","doi-asserted-by":"publisher","first-page":"86S","DOI":"10.1097\/01.AOG.0000514919.44544.95","volume":"129","author":"H Hoshiai","year":"2017","unstructured":"Hoshiai H, Seki Y, Kusumoto T, et al. Phase 2 study of relugolix vs placebo in heavy menstrual bleeding associated with uterine fibroids [abstract no. 17H]. Obstet Gynecol. 2017;129(Supp 1):86S.","journal-title":"Obstet Gynecol"},{"issue":"4 Suppl","key":"1105_CR10","first-page":"e654","volume":"195","author":"ND Shore","year":"2016","unstructured":"Shore ND, Bailen JL, Pieczonka C, et al. Testosterone lowering, PSA response and quality of life in patients with advanced hormone sensitive prostate cancer receiving TAK-385, an oral GNRH antagonist: phase 2 interim analysis [abstract no. PD28-01]. J Urol. 2016;195(4 Suppl):e654.","journal-title":"J Urol"},{"key":"1105_CR11","doi-asserted-by":"crossref","unstructured":"Saad F, Bailen JL, Pieczonka CM, et al. Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts) [abstract no. 200]. J Clin Oncol. 2016;34(2 Suppl).","DOI":"10.1200\/jco.2016.34.2_suppl.200"},{"key":"1105_CR12","doi-asserted-by":"crossref","unstructured":"Dearnaley D, Saltzstein DR, Sylvester JE, et al. Neo\/adjuvant ADT to EBRT: randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC) [abstract no. 734P]. Ann Oncol. 2016;27(Suppl 6).","DOI":"10.1093\/annonc\/mdw372.18"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01105-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01105-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01105-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T23:23:08Z","timestamp":1585610588000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01105-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1105"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01105-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"1 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. A. Markham, a contracted employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}